NASDAQ:ALMS Alumis (ALMS) Stock Price, News & Analysis $9.84 +2.60 (+35.91%) Closing price 04:00 PM EasternExtended Trading$9.68 -0.16 (-1.68%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Alumis Stock (NASDAQ:ALMS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alumis alerts:Sign Up Key Stats Today's Range$7.01▼$10.4250-Day Range$3.57▼$7.4852-Week Range$3.18▼$13.53Volume2.78 million shsAverage Volume305,515 shsMarket Capitalization$464.66 millionP/E RatioN/ADividend YieldN/APrice Target$26.00Consensus RatingBuy Company OverviewOur mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.Read More… Remove Ads Receive ALMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alumis and its competitors with MarketBeat's FREE daily newsletter. Email Address ALMS Stock News HeadlinesHC Wainwright Forecasts Alumis' Q1 Earnings (NASDAQ:ALMS)March 29, 2025 | americanbankingnews.comQ2 Earnings Forecast for Alumis Issued By Leerink PartnrsMarch 28, 2025 | americanbankingnews.comDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.April 2, 2025 | Altimetry (Ad)Alumis, Kaken Pharmaceutical enter ESK-001 collaboration and licensing agreementMarch 27, 2025 | markets.businessinsider.comAlumis Inc. Reports 2024 Results and Strategic MergerMarch 27, 2025 | tipranks.comStrategic Partnerships and Financial Projections Bolster Buy Rating for Alumis Inc.March 26, 2025 | tipranks.comAlumis stock soars on Japan dermatology dealMarch 25, 2025 | investing.comAlumis rises on licensing deal with Japan’s KakenMarch 25, 2025 | msn.comSee More Headlines ALMS Stock Analysis - Frequently Asked Questions How have ALMS shares performed this year? Alumis' stock was trading at $7.86 at the beginning of the year. Since then, ALMS stock has increased by 14.6% and is now trading at $9.01. View the best growth stocks for 2025 here. When did Alumis IPO? Alumis (ALMS) raised $210 million in an IPO on Friday, June 28th 2024. The company issued 13,125,000 shares at a price of $16.00 per share. How do I buy shares of Alumis? Shares of ALMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alumis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alumis investors own include Comstock (LODE), Ashford Hospitality Trust (AHT), Artificial Intelligence Technology Solutions (AITX), Allakos (ALLK), BioXcel Therapeutics (BTAI), Clearside Biomedical (CLSD) and Delcath Systems (DCTH). Company Calendar Today4/02/2025Next Earnings (Estimated)6/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALMS Previous SymbolNASDAQ:ALMS CIK1847367 WebN/A Phone(650) 231-6625FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$26.00 High Stock Price Target$36.00 Low Stock Price Target$13.00 Potential Upside/Downside+175.4%Consensus RatingBuy Rating Score (0-4)3.22 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio11.26 Quick Ratio11.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares47,222,000Free FloatN/AMarket Cap$445.78 million OptionableN/A BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:ALMS) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.